Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 10/20 | 0.66 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24910738 | 0.95 | NAALAD2 (0.63) | NAALAD2ALBNR1H2FOLH1KEAP1 | |
| SCHEMBL13286294 | 0.83 | ALB (0.78) | NAALAD2ALBNR1H2FOLH1KEAP1 | |
| SCHEMBL22863319 | 0.83 | NAALAD2 (0.63) | NAALAD2NR1H2KEAP1P2RY14MIF | |
| SCHEMBL16660382 | 0.83 | FOLH1 (0.57) | NAALAD2ALBNR1H2FOLH1KEAP1 | |
| SCHEMBL8893358 | 0.82 | NAALAD2 (0.62) | NAALAD2NR1H2FOLH1KEAP1MIF | |
| SCHEMBL25711649 | 0.82 | NAALAD2 (0.60) | NAALAD2ALBNR1H2KEAP1MIF | |
| SCHEMBL12754623 | 0.81 | FTO (0.65) | NAALAD2NR1H2KEAP1MIFFTO | |
| SCHEMBL9882143 | 0.79 | NAALAD2 (0.66) | NAALAD2NR1H2FOLH1KEAP1FTO | |
| SCHEMBL9881740 | 0.79 | NAALAD2 (0.64) | NAALAD2ALBFOLH1FTO | |
| SCHEMBL24910856 | 0.78 | ALB (0.51) | NAALAD2ALBNR1H2FOLH1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230016265-A1 | PSMA-TARGETING IMAGING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230016265-A1 | PSMA-TARGETING IMAGING AGENTS | FOLH1, PSMA1, PSMA2 | NAALAD2 92/4885ALB 405/4885NR1H2 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.